Cover Image
市場調查報告書

EpiCast Report:急性冠狀動脈症候群 (ACS)的流行病學預測

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

出版商 GlobalData 商品編碼 293249
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:急性冠狀動脈症候群 (ACS)的流行病學預測 EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025
出版日期: 2016年08月08日 內容資訊: 英文 79 Pages
簡介

全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的急性冠狀動脈症候群 (ACS) 和確診的患者數,從2015年的2,545萬人,預計2025年增加到3,062萬人 (年度平均增加率2.03%) 。

本報告提供全球主要7個國家的急性冠狀動脈症候群 (ACS) 調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • ACS的流行病學預測
    • ACS和確診的患者數
    • ACS和確診的患者數 (各年齡)
    • ACS和確診的患者數 (性別)
    • ACS和確診的患者數:STEMI、NSTEMI、UA
    • ACS確診的患者數 (年齡調整)
    • ACS的住院期間
    • ACS的住院期間 (性別)
    • ACS的住院期間:STEMI、NSTEMI、UA
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第3章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER124-16

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

GlobalData epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 million cases in 2015 to 30.62 million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%. In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM. In the 7MM, GlobalData epidemiologists project ACS hospitalizations to increase from 1.63 million cases in 2015 to 1.71 million cases in 2025 at an AGR of 0.51%. The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%). In the year 2015, about 29% of the ACS cases in the 7MM were STEMI, 44% were NSTEMI, and 25% were UA.

Scope

  • The Acute coronary syndrome (ACS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).
  • The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The ACS EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global ACS market.
  • Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ACS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Epidemiology

  • 2.1. Disease Background
  • 2.2. Risk Factors and Comorbidities
  • 2.3. Global Trends
    • 2.3.1. ACS Diagnosed Prevalence
    • 2.3.2. STEMI and NSTEMI Trends
    • 2.3.3. ACS Hospitalizations
  • 2.4. Forecast Methodology
    • 2.4.1. Sources Used
    • 2.4.2. Forecast Assumptions and Methods
    • 2.4.3. Sources Not Used
  • 2.5. Epidemiological Forecast for ACS (2015-2025)
    • 2.5.1. Diagnosed Prevalent Cases of ACS
    • 2.5.2. Age-Specific Diagnosed Prevalent Cases of ACS
    • 2.5.3. Sex-Specific Diagnosed Prevalent Cases of ACS
    • 2.5.4. Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA
    • 2.5.5. Age-Standardized Diagnosed Prevalence of ACS
    • 2.5.6. ACS Hospitalizations
    • 2.5.7. Sex-Specific ACS Hospitalizations
    • 2.5.8. ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA
  • 2.6. Discussion
    • 2.6.1. Epidemiological Forecast Insight
    • 2.6.2. Limitations of the Analysis
    • 2.6.3. Strengths of the Analysis

3. Appendix

  • 3.1. Bibliography
  • 3.2. About the Authors
    • 3.2.1. Epidemiologists
    • 3.2.2. Reviewers
    • 3.2.3. Global Director of Therapy Analysis and Epidemiology
    • 3.2.4. Global Head of Healthcare
  • 3.3. About GlobalData
  • 3.4. About EpiCast
  • 3.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for ACS
  • Table 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants
  • Table 3: 7MM, Sources of Diagnosed Prevalence Data for MI
  • Table 4: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI
  • Table 5: 7MM, Data Sources of ACS Hospitalizations
  • Table 6: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations
  • Table 7: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Table 8: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015
  • Table 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N (Row %), 2015
  • Table 10: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ≥25 Years, N (Row %), 2015
  • Table 11: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Table 12: 7MM, Sex-Specific ACS Hospitalizations, Ages ≥25 Years, N (Row %), 2015
  • Table 13: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ≥25 Years, Both Sexes, N, 2015

List of Figures

  • Figure 1: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008
  • Figure 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%)
  • Figure 3: Case Segmentation Map
  • Figure 4: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Figure 5; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015
  • Figure 6: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N, 2015
  • Figure 7: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ≥25 Years, N, 2015
  • Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ≥25 Years, 2015
  • Figure 9: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Figure 10: 7MM, Sex-Specific ACS, Ages ≥25 Years, N, 2015
  • Figure 11: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ≥25 Years, Both Sexes, N, 2015
Back to Top